Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study of Evacetrapib in High-Risk Vascular Disease (ACCELERATE)

This study has been completed.
The Cleveland Clinic
Information provided by (Responsible Party):
Eli Lilly and Company Identifier:
First received: September 12, 2012
Last updated: August 13, 2016
Last verified: August 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: June 2016
  Primary Completion Date: March 2016 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: August 13, 2016